US005756540A

United States Patent [19]

Lai

[11] Patent Number: 5,756,540

[45] Date of Patent: May 26, 1998

[54] **METHODS FOR IN VIVO REDUCTION OF NITRIC OXIDE LEVELS AND COMPOSITIONS USEFUL THEREFOR**

[75] Inventor: **Ching-San Lai**, Brookfield, Wis.

[73] Assignee: **MCW Research Foundation, Inc.**, Milwaukee, Wis.

[21] Appl. No.: **459,518**

[22] Filed: **Jun. 2, 1995**

[51] **Int. Cl.**[6] **A61K 31/28**; C07F 13/00; C07F 15/06

[52] **U.S. Cl.** **514/492**; 514/499; 514/501; 514/502; 556/50; 556/134; 556/148; 562/27

[58] **Field of Search** 556/40, 134, 148; 562/27; 514/492, 499, 501, 502

[56] **References Cited**

U.S. PATENT DOCUMENTS

1,863,572	6/1932	Lommel et al.	556/50
2,876,159	3/1959	Sunderman et al.	167/65
4,160,452	7/1979	Theeuwes	128/260
4,256,108	3/1981	Theeuwes	128/260
4,265,874	5/1981	Bonsen et al.	424/15
4,554,108	11/1985	Kimble et al.	260/455 A
4,595,538	6/1986	Kimble et al.	260/502.56
5,358,703	10/1994	Lai	424/9

FOREIGN PATENT DOCUMENTS

0901094 7/1962 United Kingdom .

OTHER PUBLICATIONS

Aisaka et al., "N_G-Methylarginine, an Inhibitor of Endothelium-Derived Nitric Oxide Synthesis, is a Potent Pressor Agent in the Guinea Pig: Does Nitric Oxide Regulate Blood Pressure in vivo?" *Biochem. Biophys. Res. Commun.* 160:881–886 (1989).

Aisaka et al. "L-Arginine Availability Determines the Duration of Acetylcholine-Induced Systematic Vasodilation in vivo" *Biomedical and Biophysical Research Communications* 163:710–717 (1989).

Akaike et al., "Therapeutic Effects of Imidazolineoxyl N-Oxide Against Endotoxin Shock Through its Direct Nitric Oxide-Scavenging Activity" *Biochemical and Biophysical Research Communications* 202:923–930 (1994).

Alving et al., "Increased Amount of Nitric Oxide in Exhaled Air of Asthmatics" *Eur. Respir. J.* 6:1368–1370 (1993).

Balter, Michael. "Cytokines Mive From the Margins Into the Spotlight" *Science* 268:205–206 (1995).

Barnes and Liew, "Nitric Oxide and Asthmatic Inflammation" *Immunology Today* 16:128–130 (1995).

Bartholomew, B., "A Rapid Method for the Assay of Nitrate in Urine Using the Nitrate Reductase Enzyme of *Escherichia Coli*" *Food Chem. Toxic.* 22:541–543 (1984).

Boughton-Smith et al., "Nitric Oxide Synthase Activity in Ulcerative colitis and Crohn's Disease" *Lancet* 342:338–340 (1993).

Bukrinsky et al., "Regulation of Nitric Oside Synthase Activity in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Monocytes: Implications for HIV-Associated Neurological Disease" *J. Exp. Med.* 181:735–745 (1995).

Cattell et al., "Localization of Inducible Nitric Oxide Synthase in Acute Renal Allograft Rejection in the Rat" *Transplantation* 58:1399–1402 (1994).

Clària et al., "Pathogenisis of Arterial Hypotension in Cirrhotic Rats with Ascites: Role of Endogenous Nitric Oxide" *Hepatology* 15:343–349 (1992).

Corbett et al., "Nitric Oxide Mediates Cytokine-Induced Inhibition of Insulin Secretion by Human Islets of Langerhans" *Proc. Natl. Acad. Sci.* 90:1731–1735 (1993).

Devlin et al., "Nitric Oxide Generation" *Transplantation* 58:592–595 (1994).

Dorheim et al., "Niotric Oxide Synthase Acitivity is Elevated in Brain Microvessels in Alzheimer's Disease" *Biochemical and Biophysical Research Communications* 205:659–665 (1994).

Eizirik et al., "Cytokines Suppress Human Islet Function Irrespective of Their Effects on Nitric Oxide Generation" *J. Clin. Invest.* 93:1968–1974 (1994).

Eizirik et al., "Major Species Differences Between Humans and Rodents in the Susceptibility to Pancreatic β-Cell Injury" *Proc. Natl. Acad. Sci.* 91:9253–9256 (1994).

Evans et al., "Evidence of Increased Nitiric Oxide Production in Patients with the Sepsis Syndrome" *Circulatory Shock* 41:77–81 (1993).

Evans et al., "Inhibition of Nitroc Oxide Synthase in Experimental Gram-Negative Sepsis" *Journal of Infectious Diseases* 169:343–349 (1994).

(List continued on next page.)

Primary Examiner—Porfirio Nazario-Gonzalez
Attorney, Agent, or Firm—Pretty, Schroeder, Brueggemann & Clark; Stephen E. Reiter

[57] **ABSTRACT**

In accordance with the present invention, there are provided methods for the in vivo reduction of nitric oxide levels in a mammalian subject. In contrast to the inhibitory approach described in the prior art (i.e., wherein the function of the enzymes responsible for nitric oxide production is inhibited), the present invention employs a scavenging approach whereby overproduced nitric oxide is bound in vivo to a suitable nitric oxide scavenger. The resulting complex renders the nitric oxide harmless, and is eventually excreted in the urine of the host. Further in accordance with the present invention, there are provided compositions and formulations useful for carrying out the above-described methods. An exemplary nitric oxide scavenger contemplated for use in the practice of the present invention is a dithiocarbamate-ferrous iron complex. The present invention relates to methods for reducing in vivo levels of ·NO as a means of treating subjects afflicted with inflammatory and/or infectious disease. Dithiocarbamate-containing nitric oxide scavengers are administered to a host in need of such treatment; these scavengers interact with in vivo produced ·NO, forming a stable dithiocarbamate-metal-NO complex. The NO-containing complex is then filtered through the kidneys, concentrated in the urine, and eventually excreted by the subject, thereby reducing in vivo ·NO levels.

39 Claims, 6 Drawing Sheets